Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eisai

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Experts encouraged by Alzheimer drug preliminary data

Washington (AFP) - Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.

AFP

Is This the First Alzheimer's Drug to Actually Work?

Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.

The Street

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Independent UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Drug shown to slow memory decline in Alzheimer's patients in 'historic' breakthrough

Alzheimer's Research UK said this is the first later-stage trial of an Alzheimer's drug 'in a generation' to successfully slow cognitive decline

Wales Online

Alzheimer's drug is world's first shown to slow symptoms in 'historic' breakthrough

The success of an experimental drug offers new hope to people affected by the cruel disease.

Daily Record

‘Historic’ breakthrough as dementia drug shown to slow cognitive decline

Lecanemab found to slow decline in participants’ memory and thinking caused by the brain-wasting disease by 27 per cent

Evening Standard

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Daily Mirror

Major breakthrough for dementia and Alzheimer's as drug found to reduce decline

Alzheimer’s Research UK said the finding was a “historic moment for dementia research”

Wales Online

‘Major breakthrough’ as dementia drug found to ‘slow cognitive decline’

The new clinical trial found that there was a significant reduction in the decline in memory and thinking usually seen in early-stage patients.

The Independent UK

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Volatile On Bank Of England Reversal; Apple Falls On iPhone Report, Biogen Soars On Alzheimer's Drug

Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.

Tribune News Service

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Investors Business Daily

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.

Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Investors Business Daily

Why Biogen Stock Looks 'Too Good To Ignore,' According To One Analyst

Biogen stock looks "too good to ignore," an analyst said Monday as he argued for the value of Biogen's base business.

Tribune News Service

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Benzinga

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Benzinga

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University College London

121 stories

Alzheimer Research UK

104 stories

Eisai

100 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.